GSK’s Tykerb Approval Expected; COO David Stout Talks About the Company’s New Pipeline

FDA is expected to approve GSK's new breast cancer drug, Tykerb, this week. GSK's  Chief Operating Officer David Stout discusses the drug and new vaccines in its pipeline.

Play Video

GSK's COO David Stout on Tykerb Breast Cancer Pill and New Drug Pipeline; Tykerb May be Approved This Week - Bloomberg

Bloomberg - (BLOOM)

Mar. 12, 2007. 04:32 PM EST

The COO discusses its new breast cancer drug as well as new vaccines in its pipeline.